Background {#Sec1}
==========

Human immunodeficiency virus (HIV) displays an extraordinary genetic diversity with four distinct groups: M (major), O (outlier), N (non M/O) and P (putative) with nine different subtypes (A\[A1, A2, A3, A4\], B, C, D, F\[F1, F2\], G, H, J, and K), and at least 98 circulating recombinant forms (CRFs) and multiple unique recombinant forms (URFs) within the major M Group \[[@CR1]\]. These phylogenetic classifications are currently based either on nucleotide sequences derived from multiple subgenomic regions (*gag, pol* and *env*) of the same isolates or on full-length genome sequence analysis \[[@CR2]--[@CR4]\]. The genetic diversity and rapid variation of HIV-1 have shown to influence the spectrum of mutations that develop during selective drug pressure as well as complicate the development of effective vaccines \[[@CR5]--[@CR7]\].

The prevalence of the HIV infection in Cameroon has progressively dropped from 5.5% in 2007 \[[@CR8]\] to 3.8% in 2016 \[[@CR9]\]. In Cameroon, despite the low infection rate, previous studies have revealed circulation of all group M clades (A--D, F--H, J, K), CRFs and URFs. In addition, the CRFs include; CRF01_AE, CRF02_AG, CRF06_cpx, CRF09_cpx, CRF11_cpx, CRF13_cpx, CRF18_cpx, CRF22_01A1, CRF25_cpx, CRF36_cpx and CRF37_cpx have been detected with CRF02_AG being the most common CRFs causing infection in Cameroon \[[@CR2], [@CR10], [@CR11]\]. Following this HIV-1 diversity and the presence of HIV-2, Cameroon remains an ideal Country to explore the genetic diversity of HIV-1 with a possible occurrence of diverse and unique CRFs.

Despite all this interest on HIV genetic diversity in this country, most studies have been conducted in urban and central parts of Cameroon (2, 10, 11). Studies involving other parts of the country like the NWR have not been adequately evaluated. The few studies undertaken in this region, even though sample sizes have been small (\< 30 samples), have revealed a number of new strains \[[@CR5], [@CR12]\]. Due to the preexisting diverse HIV-1 subtypes, there is a likelihood of increasing mixed infections that could lead to the development of diverse circulating recombinant forms. Based on this trend, there is a need for surveillance of these diverse HIV subtypes, CRFs, and URFs that have implications on vaccine design and transmission fitness in this region. This study was therefore conducted to ascertain the current circulating HIV subtypes, CRFs, or URFs in the Northwest region of Cameroon.

Materials and methods {#Sec2}
=====================

Study design and setting {#Sec3}
------------------------

A cross sectional study was conducted and five ART clinics systematically sampled; Bafut, Bali, Ndop and Santa District Hospitals and Bamenda Regional hospital of the NWR of Cameroon. Study participants were enrolled on the day of antiretroviral therapy (ART) initiation from February 2016 to April 2016. A standardized questionnaire and patient record file were used to collect demographic.

Ethics statement {#Sec4}
----------------

The National Ethics Committee of Cameroon approved the study protocols (NO2016/01/685/CE/CNERSH/SP). The purpose of the study and research procedures were fully explained to participants in the language (Pidgin English, English or French) best understood by the clients. Signed informed consent was obtained from each of the participants prior to the interviews and blood collection.

Study participants {#Sec5}
------------------

A total of 100 HIV-1 patients were enrolled from February 2016 to April 2016. The eligibility criteria were HIV-1 Highly active anti-retroviral therapy **(**HAART) naïve patients, male or female aged ≥18 years while the exclusion criteria were pre-exposure to HAART, and patients looking severely ill (unable to walk without support or sit up rightly). Of the 100 patients enrolled, 81(81%) samples were sequenced in required reverse transcriptase coding regions giving a successfully sequencing performance of 81%.

CD4^+^ T cell counts {#Sec6}
--------------------

The CD4^+^ T cell counts was performed using a FACS Calibur flow cytometer (Becton-Dickinson, NJ) equipped with automated acquisition and analysis software according to the manufactures instructions \[[@CR13]\].

RNA extraction, polymerase chain reaction, and sequencing {#Sec7}
---------------------------------------------------------

Five milliliters of whole blood was drawn from each subject into an EDTA (Ethylene Diamine Tetra acetic Acid) tube and centrifuged at 3000 rpm for 5 min. Two plasma aliquots of 1 ml each were collected from each patient and stored at − 80 °C until transported in an ice box to the Molecular Biology Laboratory of CIRCB-Yaoundé for analysis at CIRCB-Yaoundé where the samples were stored at − 20 °C. Plasma Viral RNA was extracted from 1 ml plasma using the QIAamp Viral RNA Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Extracted RNA was transcribed to cDNA using in-house RT --PCR protocol using a one-step kit (SuperScript™One-Step RT-PCR System, Invitrogen, USA). Partial HIV-1 *pol*-RT gene corresponding to 2075--3703 bp (the position is given referring to theHXB2 strain) was amplified by nested PCR using in-house protocol. Of the 100 samples, 81(81%) were successful amplified, purified, and directly sequenced using ABI 3130 genetic analyzer (Applied Biosystems, Foster City, CA) according to previously published in-house protocol with the following primers as shown on Table [1](#Tab1){ref-type="table"} \[[@CR14]\]. Table 1List of primersReactionNameSequencesPositionRT-PCRBS5'GAC AGG CTA ATT TTT TAG GG3′ForwardGIO25'TTT CCC CAT ATT ACT ATG CTT 3'ReverseSemi nestedBS5'GAC AGG CTA ATT TTT TAG GG3'ForwardTAK 35′ GGC TCT TGA TAA ATT TGA TAT GT 3'ReverseSequencingB5'CAG GAA TGG ATG GCC CAA AA3'ForwardF5'CCA TCC ATT CCT GGC TTT AAT 3'ReverseSEQ15'AGC AGA CCA GAG CCA ACA GC 3'ForwardSEQ25'ATT TTC CCT TCC TTT TCC ATT TC3'ReverseSEQ35'TTG TAC AGA AAT GGA AAA GGA AGG 3'ForwardSEQ45'TTT GTT CTA TGC TGC CCT ATT TCT 3'ReverseSEQ55'GGC AGC ATA GAA CAA AAA TAG AGG3'ForwardTAK 35′ GGC TCT TGA TAA ATT TGA TAT GT 3′Reverse

Phylogenetic analysis {#Sec8}
---------------------

Generated sequences were aligned using CLUSTAlW version 1.8.3 with subsequent inspection and manual modification with pair wise evolutionary distances estimated by Kimura's two-parameter method with bootstrap analysis of 1000 replicates. Resulting trees were visualized using Fig tree software. Bootstrap resampling (1000 data sets) of multiple alignments was performed to test the statistical robustness of the trees (Fig. [1](#Fig1){ref-type="fig"}). Viral recombinants were confirmed using recombinant identification program (RIP) subtyping tool available at (<http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html>). Fig. 1A Phylogenetic tree of HIV-1 pol gene. Sample sequences have red shapes. The sequences were aligned using ClustalW, and phylogenetic analysis performed using the neighbor-joining method of MEGA.v.7 software with Bootstrap value of 1000 replicates. The reference sequences were taken from the Los Alamos database (the subtype precedes the country letters code and reference accession number). Some references have been omitted to enable better visualization of the sample sequences. Abbreviation: CRF; circulating recombinant form, cpx; complex

Drug resistance {#Sec9}
---------------

HIV-1 genotypic drug resistance in the pol-RT region was defined as the presence of one or more resistance-related mutations as specified by the consensus mutation guidelines of the International AIDS Society-USA as well as consensus B subtypes <https://hivdb.stanford.edu/hivdb/by-sequences/> which were used as reference strains for the definition of mutations \[[@CR15]\].

Data analysis {#Sec10}
-------------

Statistical analysis was done using SPSS version 23 (Armonk, USA). Baseline characteristics of study patients were described using frequencies and percentages.

Results {#Sec11}
=======

The participants were aged between 18 and 61 years, with a median age of 36.9 years and 55.5% (45) were female. The mean (range) CD4^+^ T cell count was 194.3 (8--498) cells/mm^3^ and a greater part of the participants had CD4^+^ T cells count of \< 200 cells/mm^3^ 59.3% (48). The majority of the patients were residents in an Urban setting 54.3% (44) (Table [2](#Tab2){ref-type="table"}). Table 2Descriptive characteristics of study participants (*n* = 81)IndicatorVariable (n)Female (%)\
*n* = 45Male (%)\
*n* = 36SiteRural (37)24(53.3)13 (36.1)Urban (44)21(46.7)23 (63.9)Age in yearsMean ± SEM36.31 ± 1.4137.39 ± 1.51Range18--5620--61\< 30 (17)12 (70.6)5 (29.4)30--40 (37)18 (48.8)19(51.2)\> 40 (27)15 (55.6)12(44.4)CD4 Classification cells/ mm^3^Mean ± SEM207.36 ± 21.27177.97 ± 20.84Range8--48931--498\< 200 (48)23 (49.9)25 (52.1)200--350 (19)13 (68.4)6 (31.6)350--500 (14)9 (64.3)5 (35.7)

Phylogenetic analysis {#Sec12}
---------------------

From the 81 samples that were successfully amplified and sequenced, analysis of these sequences revealed; four pure subtypes and five CRF; F2 (6: 7.4%), G (4: 4.9%), D (3: 3.7%),A1 (1: 1.2%) pure subtypes and CRF02_AG (60: 74.1%), CRF22_01A1 (2: 2.4%), CRF06_cpx (1: 1.2%), CRF09_cpx (1: 1.2%) and CRF11_cpx (1: 1.2%) CRFs (Fig. [1](#Fig1){ref-type="fig"}). From this study CRF02_AG remains the most predominant circulating HIV-1 strains in Cameroon (Fig. [2](#Fig2){ref-type="fig"}). Although a small region of HIV-1 genome was amplified, new CRF in circulation in Cameroon, CRF22_01A1 (2.4%) was detected in this region. Fig. 2Graphic depiction of the distribution of HIV-1 variants. Abbreviations: CRF; circulating recombinant form, cpx; complex

Drug resistance {#Sec13}
---------------

This study shows that 9 (11.1%) patients were infected with HIV variants that carried resistance associated mutations associated with Nucleoside reverse transcriptase inhibitor (NRTI); 8.6% (7/81), Non nucleoside reverse transcriptase inhibitor (NNRTI); 4.9% (4/81) and protease inhibitors (PI); 1.2% (1/81). In this study, the most common mutations were K219Q (2.5%; 2/81) and E138A (2.5%; 2/81) which confers resistance to NRTIs and NNRTIs respectively. Singleton mutations that were associated with NRTI included: D67N, K70R, T215F, T215TA, M184MV, M184 V, D67N, K70R, K70 T, and M41ML; while that of, NNRTI was K103 N, V108I, V179E, and Y181C and for PI was I54IFV. Dual-class drug resistance mutation involving both NRTI and NNRTI was observed in three patients (3.7%).

Discussion {#Sec14}
==========

Previous studies have shown that CRF02_AG is the dominant virus circulating in Cameroon. This study showed that CRF02_AG was the dominant HIV-1 subtypes in circulation involving 74.1% of the entire samples analyzed (Fig. [2](#Fig2){ref-type="fig"}). Consistent with findings from other regions in Cameroon, this recombinant remains to be the most dominant \[[@CR10], [@CR11], [@CR16], [@CR17]\]. Cameroon is known harbor diverse HIV-1 subtypes and groups \[[@CR11], [@CR17], [@CR18]\]. By virtual of this circulating diverse HIV subtypes or CRFs, any transmission across populations has led to high viral recombinants and low pure subtypes, a situation that is being observed in Cameroon \[[@CR10], [@CR11], [@CR16], [@CR17]\].

The recombinant CRF02_AG which predominates (74.1%) in this study falls within the 48.6--80% range of previous studies conducted in Cameroon and other countries in West Africa, Central Africa, and Europe \[[@CR2], [@CR16], [@CR19]--[@CR21]\]. The high prevalence of CRF02_AG suggests that this viral strain may be well adapted in the Cameroonian population due to a founder effect from the parent strains subtype A and G, or may have some biological advantages such as a higher replicative fitness relative to parental subtype A and G which have been shown to have relatively higher replicative fitness in comparison to parental HIV-1 subtypes A and G which are known to circulate in West and East African countries \[[@CR2], [@CR10], [@CR21]\]. Thus, the high prevalence of CRF02_AG species is suggestive that CRF02_AG will certainly aid in the design of an effective vaccine.

Compared with previous studies from different urban towns in Cameroon, the prevalent subtypes after CRF02_AG were F2, G, and D contrary to detected G, F2, and D \[[@CR18]\] and D, F2, G subtypes \[[@CR17]\]. The difference in levels of diverse subtypes in this region could be associated with the diverse disease burden in regions and population migrations from one region to another either due to political instability, occupation or commercial activities.

The CRF22_01A1 variant seen in this study with a very low prevalence has not been reported in the NWR \[[@CR5], [@CR12]\].The prevalence of this variant ranges from 1.6--13.9% from previous studies carried out in other regions of Limbe, Yaounde, Douala and Bertoua \[[@CR10], [@CR11], [@CR17]\].This variant together with preceding data suggests that the CRF22_01A1 is not a new CRF strains but it might have been spread to this regions due to population migration from other regions or neighborhood countries \[[@CR11], [@CR17]\]. Introduction of this new HIV-1 variants in this region, confirms the occurrence of high levels of viral recombination that is being experienced in the country to existence of diverse HIV-1 subtypes in Cameroon.

Phylogenetic analysis of these sequences showed clusters with reference sequences from Cameroon and surrounding countries indicate possible local origins. This implies that transmissions of these viral strains are within the country.

Transmitted drug resistance (TDR) was however determined in this study. Overall prevalence of TDR was 11.1%. This prevalence was found to be higher compared to those detected (7.2%) in West and Central Africa in 2016 \[[@CR22]\]. The moderate prevalence (5--15%) seen in the NWR could be attributed to poor drug adherence, loss of follow-up, pharmacy stock-outs, lack of proper patient retention in care and the use of ARV drugs to prevent mother to child transmission or as pre and post-exposure prophylaxis that leads to acquired drug resistance \[[@CR23], [@CR24]\].

The high prevalence of NRTI over NNRTI mutations detected was contrary to previous finding in other urban centres in Cameroon \[[@CR25], [@CR26]\]. However, these findings were similar to those obtained elsewhere by Vergne et al., \[[@CR27]\] and Mbunkah et al.*,* \[[@CR28]\]. This high level of NRTIs mutations detected in this study could be associated with the shift from the use of monotherapy NNRTI to the use of HAART among HIV infected pregnant and breast feeding women in the prevention of mother to child transmission of HIV \[[@CR29], [@CR30]\]. The detected NRTIs, K219Q mutation is known to confer resistance to Zidovudine (AZT) or Stavudine (D4T) \[[@CR28]\]. Detection of this mutation could be associated with acquisition with already HIV drug resistant strains from infected individuals on either AZT or D4T treatment \[[@CR31], [@CR32]\]. Nevertheless, K103 N, V108I, V179E, and Y181C, NNRTI mutations that confer resistance to Efavirenz (EFV) and Nevirapine (NVP) were also detected \[[@CR28], [@CR33]\]. Based on the ART drug combinations, these mutations could similarly be associated with the transmission of resistant viral strains from already known populations on treatment. In this study, E138A mutation which is usually weakly selected in patients receiving second-generation NNRTIs (Rilpivirine and Etravirine) were also detected. However, detection of this mutation to these drugs could be associated with NNRTI's low genetic barrier \[[@CR26], [@CR29]\]. The detected high prevalence of E138A mutations implies that it uses as salvage therapy could be limited without effective monitoring.

Conclusions {#Sec15}
===========

Our data show an increasing diversity of HIV-1 in the NWR. This study confirmed previous findings that CRF02_AG subtype is still the most predominant subtype. In addition, the overall prevalence of TDR among recently diagnosed individuals in Northern region of Cameroun was moderate. We suggest that there is need for implementation of effective measures that could strengthen monitoring and guide ART usage and surveillance of HIV genetic diversity.
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Sequence data {#FPar1}
=============

The HIV-1 pol gene sequences were deposited at Gen Bank under accession numbers MK061035-MK061115.
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